Bevacizumab added to conventional induction chemotherapy for children with high risk neuroblastoma (BRAVEN trial)
Open Access
- 21 June 2026
- journal article
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Abstract
Despite advances in multimodal therapy, high-risk neuroblastoma (HR-NB) continues to have poor outcomes. Response to induction chemotherapy is a key predictor of long-term survival, yet intensive multi-agent regimens have not substantially improved prognosis. This study aims to evaluate the efficacy and safety of adding bevacizumab to conventional induction chemotherapy in HR-NB. This prospective, multicenter, randomized controlled trial will enroll newly diagnosed high-risk neuroblastoma patients, randomized to receive either conventional induction chemotherapy alone (control) or bevacizumab plus conventional induction chemotherapy (intervention). Response to induction therapy will be assessed according to standard criteria, and patients achieving a complete or good partial response will proceed to autologous stem cell transplantation (ASCT). All participants will be followed for at least 2 years to evaluate event-free survival (EFS) and overall survival (OS). The primary outcome, response rate, will be reported as a proportion, and EFS and OS will be analyzed using Kaplan-Meier plots and log-rank tests. The secondary outcomes (toxicity and minimal residual disease) will be reported as proportions. Prognostic factors will be evaluated with univariate and multivariate Cox regression analyses. The study aims to demonstrate that adding bevacizumab to conventional induction chemotherapy improves response rates, increases the proportion of patients eligible for autologous stem cell transplantation (ASCT), and improves survival outcomes, with manageable toxicities. This study is registered with the Clinical Trials Registry of India (CTRI/2024/09/074065, dated: 19/09/2024).Keywords
Funding Information
- Indian Council of Medical Research (Grant ID: IG/Dev.Res/00407/2027–2024 [215357]))
This publication has 26 references indexed in Scilit:
- Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlookCancer Treatment Reviews, 2020
- Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HRAnnals of Oncology, 2020
- Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG)European Journal of Cancer, 2019
- Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study)European Journal of Cancer, 2017
- Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II studyPediatric Blood & Cancer, 2017
- Outcome of children with relapsed or refractory neuroblastoma: A meta‐analysis of ITCC/SIOPEN European phase II clinical trialsPediatric Blood & Cancer, 2016
- High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trialThe Lancet Oncology, 2008
- NeuroblastomaThe Lancet, 2007
- Expression of angiogenic factors and tumor progression in human neuroblastomaJournal of Cancer Research and Clinical Oncology, 2001
- High-dose rapid schedule chemotherapy for disseminated neuroblastomaEuropean Journal of Cancer, 1992